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Continuous Spiral Stent Limbs
Couchet G., Maurel B., Sobocinski J., Hertault A., Le Roux M.,
Azzaoui R., Haulon S. Eur J Vasc Endovasc Surg 2013;46:29-33.
Aim: To evaluate the outcomes of EVAR performed with a new
generation of bifurcated endografts and limbs.
Methods: Prospectively collected data from ﬁfty consecutive patients
with abdominal aortic aneurysms (AAA) treated at our institution with
a Low Proﬁle Zenith bifurcated body/Zenith Spiral-Z legs combo
were analysed. AngioCT scans and Ultrasound exams were performed prior
to discharge. Ultrasound examination was repeated 6 months after the
procedure to assess endograft patency and to depict endoleaks.
Results: Median age was 70.6 years [50-88] and median ASA score
was 3 [2-4]. Median aortic diameter was 56B mm [49-81]. Of the 100
external iliac access vessels, 14 had a diameter of 6 mm or lower. All endog-
rafts were successfully implanted. Post-operative Ultrasound examination
and angioCT scan depicted both 1 type Ia, and 10 and 19 type 2 endoleaks
respectively. An asymptomatic thrombosis of the left external iliac artery distal
to the endograft limb was also depicted. 30-day mortality rate was 0%. Two
patients died respectively three and four months after EVAR. Both deaths
were not aneurysm related. All patients underwent an ultrasound exam 6-
12 months after EVAR. All endografts main bodies and limbs were patent.
Five endoleaks were depicted, all were type II endoleaks (the early type Ia
endoleak had sealed spontaneously; it was conﬁrmed by an angioCT scan).
One patient presented a signiﬁcant stenosis of the left iliac limb at the level
of a narrow and calciﬁed aortic bifurcation. It was successfully treated by bilat-
eral iliac angioplasty and kissing balloon stenting.
Conclusions: EVAR performed with the Zenith LP main body in
combination with Spiral-Z Iliac Legs is safe and effective. No limb occlusions
were diagnosed at the 6 month follow up even in challenging iliac anatomies
usually considered as contra indications for EVAR. Our ﬁrst results are most
satisfying and calling to be completed by a longer follow up.
Outcomes After Elective Aortic Aneurysm Repair: A Nationwide
Danish Cohort Study 2007-2010
de la Motte L., Jensen L.P., Vogt K., Kehlet H., Schroeder T.V., Lonn L.
Eur J Vasc Endovasc Surg 2013;46:57-64.
Objective: To assess outcomes after treatment for asymptomatic
abdominal aortic aneurysm (AAA) in Denmark in a period when both open
surgery (OR) and endoluminal repair (EVAR) have been routine procedures.
Methods: We performed a retrospective nationwide cohort study of
patients treated for asymptomatic AAA between 2007 and 2010. Data on
demographics, procedural data, perioperative complications, length of stay
(LOS), 30-day reinterventions and readmissions, late aneurysm and proce-
dure-related complications and mortality were obtained from the Danish
Vascular Registry and the Danish National Patient Register.
Results: 525 EVAR and 1176 OR for asymptomatic AAA were iden-
tiﬁed. LOS was shorter after EVAR than OR (4 vs 7 days, P < .001).
During primary hospitalization procedure-related complications (12% vs
6%) and general complications (21% vs 8%) were more common after
OR than EVAR (P < 0.001). The 30-day reintervention rate was higher
for OR than EVAR (18% vs 6%, P < 0.001), but there was no difference
in readmissions within 30 days. During follow-up (mean 29 6 15 months)
aneurysm-related complications after EVAR were outweighed by
procedure-related complications after OR.
Conclusion: Elective AAA repair in Denmark is overall comparable
with international results and both perioperative and late outcomes after
EVAR of elective AAA are better than the results after OR.
EVAR Deployment in Anatomically Challenging Necks Outside the
IFU
Lee J.T., Ullery B.W., Zarins C.K., Olcott C. IV, Harris E.J. Jr.,
Dalman R.L. Eur J Vasc Endovasc Surg 2013;46:65-73.
Objective: Treatment of abdominal aortic aneurysms with high-risk
anatomy (neck length <10-15 mm, neck angle >60) using commercially
available devices has become increasingly common with expandinginstitutional experience. We examined whether placement of approved
devices in short angled necks provides acceptable durability at early and inter-
mediate time points.
Methods: A total of 218 patients (197 men, 21 women) at a single
academic center underwent endovascular aneurysm repair (EVAR) with
a commercially available device between January 2004 and December
2007. Available medical records, pre- and postoperative imaging, and clin-
ical follow-up were retrospectively reviewed. Patients were divided into
those with suitable anatomy (instructions for use, IFU) for EVAR and those
with high-risk anatomic aneurysm characteristics (non-IFU).
Results: IFU (n = 143) patients underwent repair with Excluder
(40%), AneuRx (34%), and Zenith (26%) devices, whereas non-IFU (n =
75) were preferentially treated with Zenith (57%) over Excluder (25%)
and AneuRx (17%). Demographics and medical comorbidities between
the groups were similar. Operative mortality was 1.4% (2.1% IFU, 0%
non-IFU) with mean follow-up of 35 months (range 12-72). Non-IFU
patients tended to have larger sac diameters (46.7% $60 mm) with shorter
(30.7% #10 mm), conical (49.3%), and more angled (68% >60) necks (all
P < .05 compared with IFU patients). Operative characteristics revealed
that the non-IFU patients were more likely to be treated utilizing suprarenal
ﬁxation devices, to require placement of proximal cuffs (13.3% vs 2.1%, P =
.003), and needed increased ﬂuoroscopy time (31 vs 25 minutes, P = .02).
Contrast dose was similar between groups (IFU = 118 mL, non-IFU = 119
mL, P = .95). There were no early or late surgical conversions. Rates of
migration, endoleak, need for reintervention, sac regression, and freedom
from aneurysm-related death were similar between the groups (P > .05).
Conclusions: EVAR may be performed safely in high-risk patients
with unfavorable neck anatomy using particular commercially available
endografts. In our experience, the preferential use of active suprarenal ﬁxa-
tion and aggressive use of proximal cuffs is associated with optimal results in
these settings. Mid-term outcomes are comparable with those achieved in
patients with suitable anatomy using a similar range of EVAR devices. Care-
ful and mandatory long-term follow-up will be necessary to conﬁrm the
beneﬁt of treating these high-risk anatomic patients.
Centerline is Not as Accurate as Outer Curvature Length to Estimate
Thoracic Endograft Length
Kaladji A., Spear R., Hertault A., Sobocinski J., Maurel B., Haulon S. Eur J
Vasc Endovasc Surg 2013;46:82-6.
Background: To assess the accuracy of the aortic outer curvature
length for thoracic endograft planning.
Methods: Seventy-four patients (58 men, 66.4 6 14 years) who
underwent thoracic endovascular aortic repair between 2009 and 2011
treated with a Cook Medical endograft were enrolled in this retrospective
study. Immediate postoperative CT scans were analysed using EndoSize
software. Three vessel lengths were computed between two ﬁxed landmarks
placed at each end of the endograft: the straightline (axial) length, the
centerline length and the outer curvature length. A tortuosity index was
deﬁned as the ratio of the centerline length/straightline length. A Student
t test and a Pearson correlation coefﬁcient were used to examine the results.
Results: We found a signiﬁcant difference between the centerline length
(135.46 24mm) and that of the endograft (1606 29mm) (P< .0001). This
difference correlateswith the tortuosity index (r= .818,P< .0001), the endog-
raft length (r = .587, P< .0001), and the diameter of the endograft (r = .53, P
< .0001). However, the outer curvature length (161.3 6 29 mm) and the
endograft length (1606 29 mm) were similar (P = .792).
Conclusion: The outer curvature length more accurately reﬂects that
of the deployed endograft and may prove more accurate than centerlines in
planning thoracic endografts.
Perioperative Haemorrhage in Endovascular Abdominal Aneurysm
Repair Affects Outcome
Montán C., Wannberg M., Holst J., Wahlgren C.M. Eur J Vasc Endovasc
Surg 2013;46:87-92.
Objective: This study aimed to evaluate the outcome and predispos-
ing factors related to perioperative bleeding in patients treated with279
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abdominal aortic aneurysm (AAA).
Design: This was a retrospective cohort study.
Methods: A total of 525 consecutive patients (73% elective) with
AAA underwent EVAR at two vascular centres from 2008 to 2011. From
registry data perioperative bleeding was analysed in relation to outcome
and preoperative data.
Results: A total of 453 (86%) patients presented with a perioperative
bleeding <1000 mL, 42 (8%) patients 1000-1999 mL, 19 (4%) patients
2000-5000 mL and 11 (2%) >5000 mL. Other than ruptured AAA
(n = 90), no preoperative risk factors for increased perioperative bleeding
were found. Open femoral artery access (n = 101), branched (n = 18)
and uni-iliacal endografts (n = 18) and introducer size were associated
with increased perioperative bleeding (P < .001). In multivariable logistic
regression only rupture and perioperative bleeding >2000 mL were signif-
icantly related to 30-day mortality (odds ratio 10.6 (range 3.8-29.6) and
13.4 (range 4.8-37.4), respectively). Postoperative renal failure, multi-organ
failure, >5 days at intensive care unit, bowel ischaemia and abdominal
compartments syndrome were signiﬁcantly related to perioperative bleeding
>2000 mL (P < .001).
Conclusion: Large perioperative bleeding during EVAR is a clinical
problem that affects outcome. About 10% of elective AAA patients and
34% of patients with ruptured AAA, undergoing EVAR, present a perioper-
ative blood loss exceeding 1 L. In our study, a perioperative blood loss
exceeding 2 L was independently associated with increased mortality and
morbidity in both acute and elective AAA patients. Open femoral access,
branched EVAR and larger diameter introducers were associated with
increased perioperative blood loss.
Ethical application: 2011/664-31/3 (approved).Beta-blocker Use and Clinical Outcomes after Primary Vascular
Surgery: A Nationwide Propensity Score-Matched Study
Høgh A., Lindholt J.S., Nielsen H., Jensen L.P., Johnsen S.P. Eur J Vasc
Endovasc Surg 2013;46:93-102.
Objective: To explore the associations between beta-blocker use and
clinical outcomes (death, hospitalisation with myocardial infarction (MI) or
stroke, major amputation and recurrent vascular surgery) after primary
vascular reconstruction.
Methods: Patients who had primary vascular surgical or endovascular
reconstruction due to symptomatic peripheral arterial disease, in Denmark
between 1996 and 2007 were included. We obtained data on ﬁlled prescrip-
tions, clinical outcomes and confounding factors from population-based
healthcare registries. Beta-blocker users were matched to non-users by
propensity score, and Cox-regression was performed. All medications
were included as time-dependent variables.
Results: We studied 16,945matched patients (7828 beta-blocker users
and 9117 non-users) with a median follow-up period of 582 days (range, 30-
4379 days). The cumulative risks were as follows: all-cause mortality, 17.9%;
MI, 5.3%; stroke, 5.6%; major amputation, 9.1%; and recurrent vascular
surgery, 23.1%.When comparing beta-blocker users with non-users: adjusted
hazard ratio: MI, 1.52 (95% CI, 1.31-1.78); stroke, 1.21 (95% CI,
1.03-1.43); and major amputation, 0.80 (95% CI, 0.70-0.93).
Conclusion: Beta-blocker use after primary vascular surgery was
associated with a lower risk of major amputation but an increased risk
of hospitalisation with MI and stroke. No associations were found
between beta-blocker use and all-cause mortality or the risk of recurrent
vascular surgery. However, our results are not sufﬁcient to alter the indi-
cation for beta-blocker use among symptomatic peripheral arterial disease
patients.
